Clinical trial NCT02128217 (phase 1, status: completed)
Conditions: hiv-1 infection, hepatitis
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4, B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: sofosbuvir, ribavirin, ledipasvir/sofosbuvir
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1
Eligibility criteria:

        A5327 Eligibility Criteria (Cohort 1 and Cohort 2)

        Step 1 inclusion criteria for both cohorts (Cohort 1 and Cohort 2)

          -  HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or
             chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and
             confirmed by a licensed Western blot or a second antibody test by a method other than
             the initial rapid HIV and/or E/CIA, or by HIV-1 p24 antigen, or plasma HIV-1 RNA viral
             load. [NOTE: The term "licensed" refers to a FDA-approved kit, which is required for
             all IND studies.] WHO (World Health Organization) and CDC (Centers for Disease Control
             and Prevention) guidelines mandate that confirmation of the initial test result must
             use a test that is different from the one used for the initial assessment. A reactive
             initial rapid test should be confirmed by either another type of rapid assay or an
             E/CIA that is based on a different antigen preparation and/or different test principle
             (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 RNA viral
             load.

          -  A documented confirmation of acute HCV infection within 6 months prior to A5327 entry
             or HCV reinfection as described below:

               1. Acute HCV infection was defined as meeting one of the following criteria and
                  exclusion of other causes of acute hepatitis:

                    -  New (<24 weeks prior to initial A5327 entry) ALT elevation to ≥5X upper
                       limit of normal (ULN) OR >250 U/L in patients with documented normal ALT in
                       the preceding 12 months or ≥10X ULN OR >500 U/L in patients with abnormal or
                       no measured ALT baseline in the preceding 12 months with detectable HCV RNA
                       excluding those with any prior positive anti-HCV. OR

                    -  Detectable HCV RNA with prior negative anti-HCV Ab or undetectable HCV RNA
                       within the preceding 6 months.

               2. Acute HCV reinfection was defined by documentation of clearance of prior
                  infection (as evidenced by positive anti-HCV Ab) either spontaneously or after
                  treatment with two negative HCV RNA a minimum of 6 months apart AND meeting one
                  of the following criteria in addition to exclusion of other causes of acute
                  hepatitis:

                    -  New (<24 weeks prior to initial A5327 entry) ALT elevation to ≥5X ULN OR
                       >250 U/L in patients with documented normal ALT in the preceding 12 months
                       or ≥10X ULN OR >500 U/L in patients with abnormal or no measured ALT
                       baseline in the preceding 12 months with detectable HCV RNA. OR

                    -  Positive HCV RNA with prior negative HCV RNA within the preceding 6 months.

          -  HCV RNA confirmed to be detectable >12 weeks after first laboratory evidence of acute
             HCV and still within the <24 week from first laboratory evidence of acute HCV
             infection window. First laboratory evidence of infection was defined as date of first
             elevated liver enzymes or date of first serologic evidence of HCV seroconversion
             and/or viremia (whichever occurs first). [NOTE: If the screening visit occurred less
             than 12 weeks from the first laboratory evidence of infection, then the participant
             was required a pre-entry study visit to confirm detectable HCV RNA at least 12 weeks
             from the first laboratory evidence of infection had passed. It was optimal for this
             pre-entry visit to occur as close as possible to 12 weeks from first laboratory
             evidence to ensure timely treatment. Potential participants who entered screening but
             who had an undetectable HCV RNA (<LLOQ TND) at the pre-entry visit (when required)
             exhibited evidence of possible spontaneous clearance and will not meet the entry
             criteria.]

          -  Body mass index (BMI) ≥ 18 kg/m^2

          -  Screening electrocardiogram (ECG) without clinically significant abnormalities as
             determined by the investigator.

          -  Willing and able to provide written informed consent.

          -  Men and women age ≥ 18 years.

          -  All participants agreed not to participate in a conception process (eg, active attempt
             to become pregnant or to impregnate, sperm donation, in vitro fertilization). [NOTE:
             Female candidates who were pregnant or breastfeeding were not eligible. A male
             candidate who had a pregnant female partner was not eligible for the study.]

          -  When participating in sexual activity that could lead to pregnancy, all participants
             must agree to use at least two reliable forms of contraceptive simultaneously while
             receiving protocol-specified medications, and for 6 months after stopping the
             medications. Such methods included:

               -  Condoms (male or female) with or without a spermicidal agent

               -  Diaphragm or cervical cap with spermicide

               -  Intrauterine device (IUD)

               -  Tubal ligation

               -  Hormone-based contraceptive (except those containing drospirenone)

        [NOTE: Providers and participants were advised that not all contraceptive choices listed
        above can prevent HIV transmission and that some may actually increase the risk of HIV
        acquisition. Study participants who were sexually active with HIV-1 negative or unknown
        HIV-1 serostatus partners were advised that they needed to consider effective strategies
        for reducing the risk of HIV transmission, as well as meeting the requirement for effective
        contraception during their participation in the study. Study participants discussed
        contraceptive choices and HIV risk reduction methods with their health care provider.]

          -  Participants who were not of reproductive potential (women who had been
             post-menopausal for at least 24 consecutive months or had undergone hysterectomy
             and/or bilateral oophorectomy or salpingectomy or men who had documented azoospermia
             or undergone vasectomy) were eligible without requiring the use of contraceptives.
             Acceptable documentation of sterilization and menopause was specified below.

               -  Written or oral documentation communicated by clinician or clinician's staff of
                  one of the following:

               -  Physician report/letter

               -  Operative report or other source documentation in the patient record (a
                  laboratory report of azoospermia was required to document successful vasectomy)

               -  Discharge summary

               -  Follicle stimulating hormone-release factor (FSH) measurement elevated into the
                  menopausal range as established by the reporting laboratory.

          -  Intention to comply with the dosing instructions for study drug administration and
             able to complete the study schedule of assessments.

        Step 1 inclusion criteria for Cohort 1 only

          -  HIV-1 ARV therapy fell into one of the following criteria:

               1. ARV untreated, for example due to (1) lack of indication per provider (CD4 T-cell
                  count >500 cells/mm3) or (2) decision by provider and participant to defer ARV
                  therapy during the study drug dosing period (8 or 12 weeks), or (3) elite
                  controller (CD4+ >200 cells/mm3). OR

               2. On a stable, protocol-approved (didanosine (ddI), stavudine (d4T), zidovudine
                  (ZDV) excluded), ARV regimen for >8 weeks prior to screening with a CD4 T-cell
                  count >200 cells/mm3 and a documented plasma HIV-1 RNA level <50 copies/mL or <
                  lower limit of quantification (LLOQ) of local assay if LLOQ is >50 copies/mL by
                  any laboratory that has a Clinical Laboratory Improvement Amendments (CLIA)
                  certification or its equivalent ≥ 8 weeks preceding the A5327 screening visit.
                  HIV-1 RNA levels should be within 1 year of the screening visit. Screening HIV-1
                  RNA must be < 50 copies/mL as measured by any local laboratory using an
                  FDA-approved assay.

          -  Candidates must have had the following laboratory parameters within 10-42 days prior
             to study entry:

               1. Hemoglobin ≥ 12 g/dL for male, ≥11 g/dL for female participants

               2. International normalized ratio (INR) ≤1.5 x ULN unless participant was known
                  hemophilia or was stable on an anticoagulant regimen affecting INR

               3. Albumin ≥ 3 g/dL

               4. Creatinine clearance (CrCl) ≥ 60 mL/min, as calculated by the Cockcroft-Gault
                  equation (refer to section 6.3.5 for calculator utility link)

          -  Female participants of reproductive potential (defined as women who have not been
             post-menopausal for at least 24 consecutive months, ie, who have had menses within the
             preceding 24 months, or women who had not undergone surgical sterilization,
             specifically hysterectomy and/or bilateral oophorectomy or bilateral salpingectomy)
             must had a negative serum pregnancy test with a sensitivity of at least 25 mIU/mL
             performed during screening, within 48 hours prior to study entry.

        Step 1 inclusion criteria for Cohort 2 only

          -  HCV genotype 1a, 1b, or 4 infection with source documentation from a CLIA-approved
             laboratory (or its equivalent). [NOTE: Those with mixed 1a/b genotype were classified
             as 1a.]

          -  HIV-1 ARV therapy fell into one of the following criteria:

               1. ARV untreated, for example due to (1) lack of indication per provider (CD4 T-cell
                  count >500 cells/mm3) or (2) decision by provider and participant to defer ARV
                  therapy during the study drug dosing period (8 or 12 weeks), or (3) elite
                  controller (CD4+ >200 cells/mm3). OR

               2. On a stable, protocol-approved ARV regimen (the following ARVs are not allowed:
                  ddI, d4T, and TPV/r) for >8 weeks prior to screening with a CD4 T-cell count >200
                  cells/mm3 and a documented plasma HIV-1 RNA level <50 copies/mL or <LLOQ of local
                  assay if LLOQ is >50 copies/mL by any laboratory that had a Clinical Laboratory
                  Improvement Amendments (CLIA) certification or its equivalent ≥ 8 weeks preceding
                  the A5327 screening visit. HIV-1 RNA levels should be within 1 year of the
                  screening visit. Screening HIV-1 RNA must be <50 copies/mL as measured by any
                  local laboratory using an FDA-approved assay.

          -  Candidates must have had the following laboratory parameters within 10-42 days prior
             to study entry:

               1. Hemoglobin ≥9 g/dL for male and female participants

               2. International normalized ratio (INR) ≤1.5 x ULN unless participant had known
                  hemophilia or wass stable on an anticoagulant regimen affecting INR

               3. Albumin ≥3 g/dL

               4. Creatinine clearance (CrCl) ≥60 mL/min, as calculated by the Cockcroft-Gault
                  equation (refer to section 6.3.5 for calculator utility link)

          -  Female participants of reproductive potential (defined as women who had not been
             post-menopausal for at least 24 consecutive months, ie, who had menses within the
             preceding 24 months, or women who had not undergone surgical sterilization,
             specifically hysterectomy and/or bilateral oophorectomy or bilateral salpingectomy)
             must had a negative serum or urine pregnancy test within 48 hours prior to study entry
             by any laboratory or clinic that had a CLIA certificate or its equivalent, or was
             using a point-of-care (POC)/CLIA-waived test. The serum, urine or POC pregnancy test
             must had a sensitivity of at least 25 mIU/mL.

        Step 1 exclusion criteria for both cohorts (Cohort 1 and Cohort 2)

          -  Received investigational drug or device within 60 days prior to study entry.

          -  Chronic liver disease of a non-HCV etiology (eg, hemochromatosis, Wilson's disease, α1
             antitrypsin deficiency, primary sclerosing cholangitis).

          -  Presence of active or acute AIDS-defining opportunistic infections within 30 days
             prior to study entry. [NOTE: A list of AIDS-defining opportunistic infections as
             defined by the CDC, can be found in Appendix B of the following document:
             http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm]

          -  Active, serious infection (other than HIV-1 or HCV) requiring parenteral antibiotics,
             antivirals, or antifungals within 30 days prior to study entry.

          -  Infection with hepatitis B virus (HBV) defined as HBsAg positive.

          -  Evidence of acute hepatitis A infection defined as HAV IGM positive.

          -  Chronic use of systemically administered immunosuppressive agents (eg, prednisone
             equivalent > 10 mg/day).

          -  History of solid organ transplantation.

          -  Current or prior history of clinical hepatic decompensation (eg, ascites,
             encephalopathy or variceal hemorrhage).

          -  History of a gastrointestinal disorder (or post operative condition) that could
             interfere with the absorption of the study drug.

          -  History of significant or symptomatic pulmonary disease, cardiac disease, or
             porphyria.

          -  History of difficulty with blood collection and/or poor venous access for the purposes
             of phlebotomy.

          -  History of clinically significant illness or any other major medical disorder that may
             interfere with participant treatment, assessment, or compliance with study
             requirements, which may included active drug or alcohol use or dependence.

          -  Use of any prohibited concomitant medications within 30 days prior to study entry.

          -  Acute HIV infection defined as the phase immediately following infection during which
             anti-HIV antibodies are undetectable. [NOTE: Participants with early infection,
             defined as within the first 6 months of infection and with a positive HIV antibody,
             should be discussed with the A5327 protocol core team. These participants may be
             considered for inclusion in the study on a case by case basis with the specific
             documented approval of the protocol chairs.]

        Step 1 exclusion criteria for Cohort 1 only

          -  Prior exposure to a direct-acting antiviral (DAA) targeting the HCV NS5B polymerase.
             [NOTE: DAAs include but are not limited to: mericitabine, ABT-333, ABT-072, BI-207127,
             BMS-791325, VX-222, tegobuvir, IDX719, setrobuvir, GS-9669, VX-135.]

          -  History of clinically significant hemoglobinopathy (eg, sickle cell disease,
             thalassemia).

          -  Known hypersensitivity to RBV, SOF, its metabolites, or formulation excipients or any
             other contraindication to the use of RBV or SOF.

          -  Currently receiving ZDV, ddI, or d4T.

        Step 1 Exclusion criteria for Cohort 2 only

          -  Any preceding attempt at HCV treatment during this acute HCV infection episode, ie, 24
             weeks prior to entry.

          -  Known hypersensitivity to SOF or LDV, the metabolites, or formulation excipients or
             any other contraindication to the use of SOF or LDV.

          -  Currently receiving TPV/r, ddI, d4T or amiodarone.

          -  Pregnancy or Breastfeeding.